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Background: The identiﬁcation of Pseudomonas aeruginosa (P. aeruginosa) isolates in sputum from cystic ﬁbrosis (CF) patients can be
challenging due to the multitude of phenotypic changes isolates undergo during adaptation to the microenvironment of the CF lung.
Methods: We report the occurrence of shared P. aeruginosa isolates which failed identiﬁcation by phenotypic methodologies and required species
speciﬁc polymerase chain reaction. P. aeruginosa isolates were genotyped by macrorestriction analysis.
Results: Analysis of atypical isolates revealed one clonal P. aeruginosa isolate and three smaller clusters. In contrast molecular typing of
phenotypically characteristic P. aeruginosa isolates revealed only small clusters. Despite exhibiting higher levels of antimicrobial resistance,
acquisition of atypical strains was not associated with signiﬁcant changes in clinical decline.
Conclusions: Our experience highlights the importance of accurate identiﬁcation of bacterial isolates in CF lung disease to detect clonal spread of
atypical isolates.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pseudomonas aeruginosa; Molecular identiﬁcation; Genotyping1. Introduction
Pseudomonas aeruginosa (P. aeruginosa) is an opportu-
nistic pathogen and is the most frequently isolated pathogen
from sputum of patients with cystic fibrosis (CF) lung
disease. Approximately 80% of CF patients are infected with
P. aeruginosa and lung infections have been associated with
increased morbidity and mortality [1]. Accurate identification
of P. aeruginosa is important for both patient management
and infection control strategies.
Biochemical identification of P. aeruginosa in CF lung
disease is complicated as P. aeruginosa adapts to the
microenvironment of the CF lung by undergoing a multitude⁎ Corresponding author at: Department of Medical Microbiology, St. Vincent'
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http://dx.doi.org/10.1016/j.jcf.2012.07.007slishedof phenotypic changes including loss of pigment production,
alginate production (mucoidy), loss of motility and synthesis
of rough lipopolysaccharide [2]. In addition P. aeruginosa
modifies its metabolic strategy to adapt to the limited oxygen
concentrations available when growing in the thick mucus
layers of the CF lung. Energy generation by P. aeruginosa in
the hypoxic microenvironment of the CF lung can occur
through microaerophilic respiration, aerobic and anaerobic
denitrification and possibly arginine and pyruvate fermenta-
tion [3].
These phenotypic and metabolic adaptations, together with
the presence of multiple other bacterial species encountered in
the CF lung, complicate biochemical identification of organisms
by manual methods (API 20 NE) and commercial identification
systems [4]. Several studies have highlighted the need for the
development and application of molecular techniques to correctly
identify P. aeruginosa and other non-fermenter bacteria in CF
lung disease [5,6].by Elsevier B.V. All rights reserved.
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around the world have documented the occurrence of clonal
P. aeruginosa strains among their patient populations [7–10].
In general clonal strains were phenotypically identifiable as
P. aeruginosa, associated with increased antibiotic resistance
and genetic relatedness was detected by pulsed-field gel
electrophoresis (PFGE). Among Irish CF centres a clonal
strain has so far only been reported once from a paediatric
centre [11].
We report here the occurrence of genetically related
P. aeruginosa strains phenotypically identifying as ‘Moraxella’
species by API 20 NE. These isolates were identified as
P. aeruginosa by molecular testing. Genotyping of these strains
revealed one dominant clone of P. aeruginosa along with three
smaller clusters. Atypical P. aeruginosa isolates were highly
resistant to front-line antipseudomonal antibiotics used for the
treatment of respiratory exacerbations in Cystic Fibrosis.2. Material and methods
2.1. Clinical setting
The National Adult Centre at St. Vincent's University
Hospital manages approximately 300 CF patients. 72.4% are
infected with P. aeruginosa. At the beginning of this study
patients admitted to hospital and patients attending outpatient
clinics were segregated by infection status when positive for
P. aeruginosa, Burkholderia cepacia complex or meticillin-
resistant Staphylococcus aureus. Patients were attending pae-
diatric CF centres in Dublin before being referred to the adult
services of this hospital. For the majority of patients sputum
specimens were collected at 3 monthly intervals. Isolates
analysed in this study were collected from 2005 to 2007. One
isolate per patient was included in this study.2.2. Culture and biochemical identification
Sputum specimens were cultured routinely on MacConkey
agar, B. cepacia specific agar, mannitol salt agar and non-
selective media (Columbia blood agar, Chocolate agar) (all
obtained from Fannin Limited, Dublin, Ireland). P. aeruginosa
isolates were phenotypically identified by colony morphology
(mucoid or nonmucoid), green/blue pigmentation of colonies,
positive oxidase reaction and resistance to C 390 (chloro-
9-[4-[diethylamino] phenyl]-9, 10-dihydro-10-phenylacridine
hydrochloride) (Rosco, Denmark). All Gram-negative,
oxidase positive isolates which were not phenotypically
identified as P. aeruginosa were subjected to API 20 NE
analysis (bioMerieux, Marcy l'Etoile, France). These isolates
are hereafter referred to as ‘atypical strains’. Biochemical
identification was performed according to the manufacturer's
instructions.
Antibiotic susceptibility testing was performed on Isosensitest
agar (Fannin Limited, Dublin, Ireland) according to the British
Society of Antimicrobial Chemotherapy guidelines.2.3. Bacterial DNA isolation
DNA was isolated from cultures of organisms grown
overnight on Columbia blood agar at 37 °C. A single isolated
colony was suspended in nuclease-free water. Suspensions were
boiled for 10 min and subsequently centrifuged at 2500 rpm for
5 min. The supernatant was directly used for PCR analysis.
2.4. PCR amplification
PCR was carried out as described by Spilker et al. using 16S
ribosomal DNA as target [5]. Amplification was performed in
a 25 μl reaction volume containing 2.5 μl 10× buffer (New
England Biolabs, USA), 250 μM of each deoxynucleoside
triphosphate (Roche), 0.8 μM of forward (PA-SS-F) and
reverse primer (PA-SS-R), 1 U of Taq DNA polymerase
(New England Biolabs, USA) and 10 μl of whole-cell bacterial
lysate adjusted to a total volume of 25 μl. Amplification was
carried out in a Storm thermocycler with an initial denaturation
step of 2 min at 95 °C followed by 25 cycles of 20 s at 94 °C,
20 s at 56 °C and 40 s at 72 °C. Amplicons were detected by
electrophoresis in a conventional 1.5% agarose gel in 0.5×
tris-borate-EDTA buffer. Gels were subsequently stained with
ethidium bromide and viewed under UV light.
2.5. Pulsed-field gel electrophoresis (PFGE)
PFGE was performed with contour-clamped homogenous
electric field CHEF mapper equipment (Bio-Rad Laboratories)
in 1.2% agarose at 14 °C, and a voltage of 200 V and a pulse
rate of 5 s to 60 s, using the restriction enzyme SpeI. Gels were
imaged as described above and analysed using Fingerprinting
software (FPQuest, Version 4.5, Bio-Ra).
2.6. Patient data
All patients infected with atypical P. aeruginosa isolates
were identified. Clinical and demographic data were obtained
from each patient's medical chart for the 2-year period before
and after infection with atypical P. aeruginosa isolates. Clinical
variables analysed included forced expiratory volume (FEV1),
forced expiratory vital capacity (FVC) and body mass index
(BMI), exacerbation history including total number of inpatient
hospital days and total days on IV antibiotics.
2.7. Statistical analysis
Annual rate of change in FEV1 (% predicted) was the
primary outcome of interest. Secondary outcomes included rate
of change in BMI, frequency of pulmonary exacerbations and
total number of days in hospital and total number of days on
IV antibiotics. Age, gender, and sputum microbiology were
included in the regression analysis as possible confounders/
effect modifiers. Generalised estimating equations were used
to analyse longitudinal changes in FEV1 and BMI. Wilcoxon
signed-rank test was used to compare exacerbation data pre-
and post-exposure to atypical P. aeruginosa isolates. Antibiotic
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acteristic P. aeruginosa strains were compared with chi-square
test.
3. Results
The occurrence of an increasing number of non-fermenter
bacteria from CF sputum specimen, identifying poorly as –
‘Moraxella’ – species on API 20 NE prompted us to initiate
molecular identification techniques. Analysis of the first non-
fermenter bacteria by species-specific P. aeruginosa PCR
revealed a high percentage of these strains as P. aeruginosa
isolates (Table 1). Therefore the conventional identification
approach for non-fermenter bacteria from CF sputum specimen
was changed, and all non-fermenter isolates with suboptimal
(less than ‘excellent’ or ‘very good’) phenotypic identification
by API 20 NE were subjected to molecular analysis. Only
isolates with – ‘excellent’ – or – ‘very good’ – identification by
API 20 NE were reported along with their biochemical
identification profile. Sixty-two percent (48 of 78) of the
isolates with suboptimal biochemical identification initially
tested were reclassified as P. aeruginosa by molecular methods
(Table 1), whereas no isolate with – ‘excellent’ – or – ‘very
good’– biochemical identification needed to be reclassified
after molecular testing (data not shown). The most frequent API
20 NE identification profile recorded for these isolates was
‘Moraxella species’, other biochemical profiles encountered are
listed in Table 1. During the study period 11.6% (260 out of
2242) of CF P. aeruginosa isolates investigated in the laboratory
were classified as ‘Moraxella species’ by API 20 NE. All of the
investigated isolates showed the same morphotype: non-mucoid,
non-pigmented and oxidase positive.
To investigate a potential clonal relationship among atypical
P. aeruginosa isolates, these were analysed by pulsed field gel
electrophoresis (PFGE). Among 48 atypical isolates tested,
PFGE revealed 16 non-related strains with unique banding
patterns. The remaining 32 isolates grouped into one clonal
strain (denoted as PFGE pulsotype 1) recovered from 23Table 1
Genotypic identification and PFGE typing results of non-lactose fermenters
with suboptimal a phenotypic identification isolated from CF sputum specimen.
API 20 NE identification No
tested
P. aeruginosa
PCR+ve
PFGE typing
result
Moraxella species 44 43 11 unique,
4 pulsotype groups b
Comomonas testosteroni 9 4 Unique
Chryseomonas species 2 0 –
Achromobacter xylosidans 7 0 –
Stenotrophomas maltophilia 7 0 –
Brevundimonas versicularis 2 0 –
Aeromonas species 1 0 –
Ralstonia pickettii 2 1 Unique
Chryseobacterium indologenes 2 0 –
Sphingobacterium spiritovorium 2 0 –
Total no. 78 48
a Suboptimal identification was defined as any API 20 NE identification less
than ‘excellent’ or ‘very good’.
b Cluster analysis of the 4 pulsotype groups is shown in Fig. 1.patients (only 18 profiles shown in Fig. 1) and 3 smaller
clusters (Fig. 1). Isolates with PFGE pulsotype-2 were cultured
from 4 patients, pulsotype-3 from 3 patients and pulsotype-4
from 2 patients (Fig. 1). Pulsotype 2, 3 and 4 clusters were
unrelated to the major clonal strain and were unrelated to each
other.
In contrast PFGE analysis of 100 CF P. aeruginosa isolates
collected during the same time period with characteristic
phenotype (as defined in Material and methods) only revealed
miniclusters with up to 2 patients but no larger clonal groupings
(Fig. 2). The majority of patients infected with atypical isolates
were frequently co-infected with phenotypically characteristic
P. aeruginosa isolates, only a few patients had not grown
identifiable P. aeruginosa previously. The frequency of co-
infection with characteristic P. aeruginosa isolates was 78%
in pulsotype-1 group, 75% in pulsotype-2 group, 100% in
pulsotype-3 and pulsotype-4 group and 88% among patients
infected with atypical unique isolates. Over the subsequent
years sputum specimens remained persistently positive for
clonal pulsotype-1 strain in the majority of patients.
Atypical P. aeruginosa isolates revealed higher levels
of antibiotic resistance than phenotypically characteristic
P. aeruginosa isolates (Table 2). Analysis of clinical data showed
that acquisition of atypical P. aeruginosa was not associated
with a change in rate of decline in FEV1 (% predicted) or BMI
(% baseline) (Table 3). Post-exposure rate of decline in FEV1
(% predicted) was similar to that reported with colonization with
phenotypically characteristic P. aeruginosa [12]. There was no
significant change in exacerbation frequency, total days in
hospital or total days on IV antibiotics after exposure to atypical
P. aeruginosa isolates (Table 3).
4. Discussion
Over the last decade an increasing number of studies have
reported the infection of unrelated patients by distinct strains
of P. aeruginosa implying patient-to-patient spread or ac-
quisition from a common environmental source [10]. The
majority of clonal strains were detected through characteristic
antibiograms or through routine genotyping efforts applied
to these P. aeruginosa isolates [13,8,10].
Ireland has the highest incidence of CF worldwide with an
estimated incidence of 1/1353 live births [14]. Despite the high
incidence of CF disease clonal P. aeruginosa strains have so
far only been reported once from a paediatric hospital in the
Republic of Ireland. We document here the occurrence of a
clonal P. aeruginosa strain among an adult CF population,
which could only be detected by initiating molecular identifi-
cation techniques.
The shortcomings of biochemical identification techniques
applied to unusual Gram-negative, oxidase-positive rods were
published previously [6]. Only 17% of unusual isolates were
correctly identified by API 20 NE and an agreement between
biochemical and molecular identification was only achieved for
isolates with ‘excellent identification’ by API 20 NE [6]. Data
recently published by the EuroCareCF quality assessment group
reveals problems and delays encountered by many European CF
Fig. 1. Cluster analysis of SpeImacrorestriction profiles of 27 atypical P. aeruginosa isolates available for analysis. Four distinct pulsotypes were identified by PFGE.
Pulsotype 1 was isolated from 23 patients [only 18 patient profiles shown], pulsotype 2 from 4 patients, pulsotype 3 from 3 patients and pulsotype 4 from 2 patients.
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finding of a clonal P. aeruginosa strain, which was only correctly
identified by species-specific PCR further highlights the need for
molecular or mass spectrometry based identification techniques
in the routine CF microbiology laboratory to support more
routine approaches.
Prompt identification of P. aeruginosa isolates is important to
be able to initiate effective therapy immediately and to facilitate
segregating of CF patients according to their colonization status.
Most of the CF patients infected with the clonal P. aeruginosa
strain were co-infected with typical P. aeruginosa strains. All
of the patients harbouring the clonal strain had been attending
paediatric CF centres in Dublin before being transferred to the
service of this hospital. Acquisition of the clonal P. aeruginosa
isolate could therefore have happened in different locations. The
identification of genetically related P. aeruginosa strains among
CF patients led to the implementation of a strict segregation
policy in the hospital to minimize any possible contact between
CF patients (October 2007). Typing data obtained by the
University of Edinburgh suggested that this isolate had not been
detected in other centres in Ireland nor the UK (data not shown).Atypical P. aeruginosa strains appeared to be highly
adapted to the CF lung and had an increased antibiotic re-
sistance profile compared to phenotypically characteristic
P. aeruginosa strains. More than 50% of isolates were resistant
to tobramycin, meropenem, ceftazidime and aztreonam. The
highest level of resistance among β-lactam antibiotics was
observed for meropenem (79% of isolates resistant), which is
higher than reported for other transmissible strains [9]. 31%
of atypical isolates were resistant to colistin. Similar colistin
resistance rates had been reported previously for CF patients
treated with nebulized colistin [16].
Acquisition of such a highly adapted strain of P. aeruginosa is
likely to have adverse consequences compared to the acquisition
of a unique environmental strain, which may be successfully
eradicated if detected early with oral and nebulised antibiotics.
Previous studies reported clonal isolates to be more virulent and
to be associated with a more rapid decline in lung function
[13,17]. Patients infected with the clonal strain in this study did
not show significant changes in clinical outcomes for CF patients.
There was no significant change in FEV1 (% predicted) or body
mass index (% baseline), exacerbation frequency, total days in
Fig. 2. Cluster analysis of SpeI macrorestriction profiles of phenotypically characteristic P. aeruginosa isolates.
Table 2
Antimicrobial resistance profile of atypical versus phenotypically characteristic
P. aeruginosa isolates.
Antimicrobial agent Atypical
P. aeruginosa
Typical
P. aeruginosa
P value
Meropenem 79 48 pb0.0001
Ceftazidime 71 37 pb0.0001
Piperacillin/Tazobactam 35 21 p=0.0009
Aztreonam 62 32 pb0.0001
Ciprofloxacin 35 37 p=0.7147
Colistin 31 5 pb0.0001
Tobramycin 77 28 pb0.0001
Gentamicin 90 52 pb0.0001
Amikacin 86 45 pb0.0001
Cotrimoxazol 88 100 pb0.0001
Antibiotic susceptibilities of 260 atypical P. aeruginosa strains (identifying as –
‘Moraxella’ – species on API 20 NE) isolated during the study period were
compared with 260 phenotypically characteristic P. aeruginosa strains. Data are
presented as % of isolates resistant to the given antibiotic. Chi-square test was
used to compare resistance data.
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clonal isolate.
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